{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Esophagogastric+Tumors", "query": { "condition": "Esophagogastric Tumors" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 48, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Esophagogastric+Tumors&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-11T02:19:06.561Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00004235", "title": "Docetaxel and Irinotecan in Treating Patients With Advanced Cancer of the Esophagus or Stomach", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2000-01", "completion_date": "2004-08", "has_results": false, "last_update_posted_date": "2016-07-14", "last_synced_at": "2026-06-11T02:19:06.561Z", "location_count": 18, "location_summary": "Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 15 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Cedar Rapids", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004235" }, { "nct_id": "NCT01285557", "title": "Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction" ], "interventions": [ { "name": "S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm)", "type": "DRUG" }, { "name": "Fluorouracil/cisplatin (control arm)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 361, "start_date": "2011-04-14", "completion_date": "2014-08-15", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-06-11T02:19:06.561Z", "location_count": 4, "location_summary": "Alexandria, Louisiana • Albuquerque, New Mexico • Dallas, Texas + 1 more", "locations": [ { "city": "Alexandria", "state": "Louisiana" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01285557" }, { "nct_id": "NCT02013154", "title": "A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Esophageal Neoplasms", "Adenocarcinoma of the Gastroesophageal Junction", "Gastroesophageal Cancer", "Squamous Cell Carcinoma", "Gastric Adenocarcinoma" ], "interventions": [ { "name": "DKN-01 150 mg", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "DKN-01 300 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Leap Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 151, "start_date": "2014-05-05", "completion_date": "2021-01-11", "has_results": false, "last_update_posted_date": "2025-08-03", "last_synced_at": "2026-06-11T02:19:06.561Z", "location_count": 10, "location_summary": "Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02013154" }, { "nct_id": "NCT00137813", "title": "Avastin and Taxotere for Esophagogastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2004-08", "completion_date": "2009-09", "has_results": false, "last_update_posted_date": "2018-11-01", "last_synced_at": "2026-06-11T02:19:06.561Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00137813" }, { "nct_id": "NCT00447330", "title": "Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Neoplasms", "Stomach Neoplasms", "Neoplasm Metastasis" ], "interventions": [ { "name": "capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2007-02", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2015-02-13", "last_synced_at": "2026-06-11T02:19:06.561Z", "location_count": 2, "location_summary": "Durham, North Carolina • Winston-Salem, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00447330" }, { "nct_id": "NCT03610711", "title": "REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastroesophageal Cancer", "Immune Checkpoint Inhibition" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Relatlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 21, "start_date": "2019-03-06", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-06-11T02:19:06.561Z", "location_count": 3, "location_summary": "Baltimore, Maryland • Pittsburgh, Pennsylvania • Dallas, Texas", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03610711" }, { "nct_id": "NCT02358863", "title": "Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "Modified FOLFOX6", "type": "DRUG" }, { "name": "Docetaxel/Capecitabine", "type": "DRUG" }, { "name": "Cisplatin/Irinotecan", "type": "DRUG" }, { "name": "Cisplatin/Docetaxel", "type": "DRUG" }, { "name": "IRI/EPI", "type": "DRUG" }, { "name": "EPI/Docetaxel", "type": "DRUG" }, { "name": "Irinotecan/Docetaxel", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2015-02", "completion_date": "2016-11", "has_results": true, "last_update_posted_date": "2018-09-06", "last_synced_at": "2026-06-11T02:19:06.561Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02358863" }, { "nct_id": "NCT05544929", "title": "A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Cutaneous Melanoma", "Carcinoma, Renal Cell", "Carcinoma, Ovarian Epithelial", "Nasopharyngeal Carcinoma", "Carcinoma, Thymic", "Anal Cancer", "Mesothelioma", "Esophagogastric Cancer", "High Microsatellite Instability Colorectal Carcinoma", "Squamous Cell Carcinoma of Head and Neck", "Triple Negative Breast Neoplasms" ], "interventions": [ { "name": "KFA115", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 126, "start_date": "2022-10-26", "completion_date": "2027-09-01", "has_results": false, "last_update_posted_date": "2026-01-06", "last_synced_at": "2026-06-11T02:19:06.561Z", "location_count": 5, "location_summary": "Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05544929" }, { "nct_id": "NCT07132918", "title": "HEARTS Trial for Thoracic Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer (Stage III)", "Esophageal Cancer Stage I-III", "Esophagogastric Cancer Stage I-III", "Thymoma and Thymic Carcinoma Stage II-III", "Other Cancers in the Thoracic Region" ], "interventions": [ { "name": "MRgART", "type": "RADIATION" }, { "name": "LINAC", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2025-10-08", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-06-11T02:19:06.561Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT07132918" }, { "nct_id": "NCT01769508", "title": "Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2 Positive Esophagogastric Cancer" ], "interventions": [ { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Lapatinib", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2013-02", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2016-06-13", "last_synced_at": "2026-06-11T02:19:06.561Z", "location_count": 9, "location_summary": "Fort Myers, Florida • Orlando, Florida • Pensacola, Florida + 6 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Pensacola", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Gainesville", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01769508" } ] }